Stock Market Reviews

AORT (Artivion, Inc.) News

Get the latest news, insights, and market updates on AORT (Artivion, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Artivion (AORT) Tops Q3 Earnings and Revenue Estimates
  Artivion (AORT) delivered earnings and revenue surprises of +14.29% and +1.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $AORT
• Artivion Reports Third Quarter 2025 Financial Results
  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2025.
  Nov 6, 2025 - $AORT
• Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent Graft System ("Arcevo LSA") in the treatment of acute and chronic arch pathologies. The trial is designed to support the Company's forthcoming application to the U.S. Food and Drug Administration (FDA) for Premarket Approval (PMA) of Arcevo LSA
  Nov 6, 2025 - $AORT
• Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates
  Inogen (INGN) delivered earnings and revenue surprises of +9.09% and -0.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $AORT
• Artivion (AORT) Reports Q3: Everything You Need To Know Ahead Of Earnings
  Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after market hours. Here’s what to expect.
  Nov 5, 2025 - $AORT
• Why Artivion (AORT) Is Up 5.2% After Raising Its 2024 Outlook and Highlighting Product Momentum
  Artivion reported strong fiscal second-quarter earnings and raised its full-year outlook, citing renewed momentum in mechanical heart valves and continued adoption of its new aortic stent graft. Progress on the U.S. clinical pathway for the company’s aortic arch device and clear operating leverage were additionally highlighted by management, signaling operational and product-driven growth. Now, we'll assess how the increased full-year outlook and enhanced product momentum could reshape...
  Oct 31, 2025 - $AORT
• Strong Results and Improved Guidance Lifted Artivion (AORT)
  Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward trajectory in the quarter, with the S&P 500 Index surging 8.12%. Class A shares of the fund underperformed the Russell 2500 Growth Index […]
  Oct 29, 2025 - $AORT
• Artivion to Participate in the Stifel 2025 Healthcare Conference
  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at the Lotte New York Palace Hotel. The Company's fireside chat is scheduled to begin at 8:00 a.m. ET.
  Oct 29, 2025 - $AORT
• 3 Healthcare Stocks We Find Risky
  From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 13.5% has lagged the S&P 500’s 22.9% climb.
  Oct 24, 2025 - $AORT
• Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.
  Oct 23, 2025 - $AORT